VALNEVA - BUY | EUR15 (+64%) Strengthening vaccines pipeline in the post-COVID era
Post-COVID, we believe governments and investors will step up their focus on the infectious disease vaccines. We expect Valneva to benefit from this trend as a fully integrated pure-play vaccine company with two products on the market and two attractive late-stage candidates. In this report, we highlight the expected 2023 launch of the VLA1553 vaccine for prevention of Chikungunya disease. While we model a sales trajectory in the traveller market, we believe that with changing climate patterns, the vaccine could also be relevant for a potential pandemic preparedness.Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Valsoia SPA. Valsoia SpA is an Italy-based company active in the food industry. The Company is engaged in the production, distribution and marketing of food products, related to healthy nutrition. Its core activity is the production of soy food products that includes vegetable drinks, ice cream, yogurts, vegetable desserts, vegetable ready meal solutions and other vegetarian products. The Company distributes in Italy products of Weetabix and markets its own products under four brand names: Valsoia Bonta e Salute, Rys Riso e Benessere, Vitasoya and Naturattiva. The Company sells its products across Europe, including Austria, Germany, Greece, Slovenia, Spain, Switzerland and Finland, among others. As of December 31, 2011, the Company operated through three subsidiaries: J&T Italia Srl (Italy), Valsoia Pronova doo (Slovenia) and Valsoia Iberica SL (Spain).
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.